BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. …
Over the last 12 months, insiders at BioMarin Pharmaceutical Inc. have bought $0 and sold $23.82M worth of BioMarin Pharmaceutical Inc. stock.
On average, over the past 5 years, insiders at BioMarin Pharmaceutical Inc. have bought $658,092 and sold $25.82M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 3,625 shares for transaction amount of $314,469 was made by Alles Mark J (director) on 2022‑10‑31.
2024-08-13 | Sale | GVP, Chief Accounting Officer | 714 0.0004% | $90.00 | $64,260 | 0.00% | ||
2024-05-30 | Sale | EVP, Chief Financial Officer | 5,000 0.0027% | $75.19 | $375,950 | +12.73% | ||
2024-05-28 | Sale | EVP, Chief Legal Officer | 40,850 0.0215% | $74.51 | $3.04M | +12.62% | ||
2024-05-10 | Sale | director | 20,000 0.0105% | $81.14 | $1.62M | -0.40% | ||
2024-05-09 | Sale | director | 20,000 0.0105% | $81.62 | $1.63M | -1.16% | ||
2024-05-02 | Sale | EVP, Chief Commercial Officer | 5,000 0.0026% | $82.91 | $414,550 | -2.44% | ||
2024-05-02 | Sale | EVP, Chief Legal Officer | 1,850 0.001% | $85.01 | $157,269 | -2.44% | ||
2024-04-12 | Sale | director | 20,000 0.0104% | $91.26 | $1.83M | -10.61% | ||
2024-04-11 | Sale | director | 20,000 0.0105% | $90.99 | $1.82M | -9.79% | ||
2024-04-10 | Sale | GVP, Chief Accounting Officer | 2,286 0.0012% | $90.00 | $205,740 | -8.46% | ||
2024-03-28 | Sale | EVP, Chief Legal Officer | 24,602 0.0132% | $88.34 | $2.17M | -4.39% | ||
2024-03-06 | Sale | director | 1,000 0.0005% | $86.71 | $86,713 | -3.09% | ||
2024-03-05 | Sale | director | 1,000 0.0005% | $85.51 | $85,510 | -2.27% | ||
2024-03-05 | Sale | President, Worldwide R&D | 35,341 0.0186% | $85.18 | $3.01M | -2.27% | ||
2024-03-05 | Sale | EVP, Chief Commercial Officer | 4,000 0.0021% | $87.07 | $348,280 | -2.27% | ||
2024-02-27 | Sale | director | 1,000 0.0005% | $90.35 | $90,350 | -7.15% | ||
2024-02-09 | Sale | director | 15,000 0.0078% | $88.28 | $1.32M | -4.40% | ||
2024-02-08 | Sale | director | 15,000 0.0079% | $89.77 | $1.35M | -4.04% | ||
2024-01-10 | Sale | director | 10,000 0.0054% | $96.38 | $963,800 | -10.86% | ||
2024-01-09 | Sale | director | 10,000 0.0054% | $98.19 | $981,900 | -10.91% |
BIENAIME JEAN JACQUES | director | 474994 0.2492% | $65.86 | 26 | 321 | +29.88% |
Mueller Brian | EVP, Chief Financial Officer | 72159 0.0379% | $65.86 | 2 | 32 | +36.78% |
Davis George Eric | EVP, Chief Legal Officer | 56157 0.0295% | $65.86 | 4 | 73 | +5.04% |
MEIER RICHARD A | 104032 0.0546% | $65.86 | 4 | 9 | +42.46% | |
PRICE FREDRIC D | Chief Executive Officer | 79285 0.0416% | $65.86 | 1 | 0 | <0.0001% |
PRIMECAP Management Co | $1.63B | 9.86 | 18.71M | +1.63% | +$26.16M | 1.2 | |
The Vanguard Group | $1.58B | 9.54 | 18.12M | +0.37% | +$5.86M | 0.03 | |
BlackRock | $1.26B | 7.63 | 14.48M | -1.38% | -$17.72M | 0.03 | |
Dodge & Cox | $1.22B | 7.37 | 13.99M | <0.01% | -$97,820.80 | 0.71 | |
State Street | $602.23M | 3.63 | 6.9M | +2.45% | +$14.38M | 0.03 |